Research & Development
GT Biopharma Promotes Raymond W Urbanski MD, PhD to President, CMO
16 May 2018 - - Washington, DC-based immuno-oncology biotechnology company GT Biopharma Inc. (OTCQB: GTBP; Euronext Paris: GTBP.PA) has advanced Dr. Raymond W Urbanski MD, PhD to the position of president and chief medical officer, effective immediately, the company said.
Since joining the company in October 2017, Urbanski has been instrumental in driving key milestones and initiatives including the transitioning the first TriKE IND from the University of Minnesota to GT Biopharma while engaging the FDA in preparation for human clinical testing to begin in 2H 2018; implementing processes to expedite the identification and development of future tumor antigen targets; driving forward our Bi-specific Antibody Drug Conjugate platform which included the formation of our Antibody-Drug Conjugate Clinical advisory board.
Urbanski has also been a major factor in developing a strong working relationship with the University of Minnesota, Masonic Cancer Center, the epicenter of innovation for the TriKE and TetraKE platforms.
GT Biopharma is focused on innovative treatments based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs and TetraKEs) and bispecific antibody-drug conjugate platforms.
Its lead oncology drug candidate, OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. GT's TriKE platform will address a number of cancer types.
GT's nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (neurology and pain) and shepherding them through the approval process to the NDA. GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.


Related Headlines